Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment And Alzheimer’s Disease In The AIBL Study Of Aging
Authors/Creators
Wayne R. Leifert
Jannatul F. Tuli
Maxime François
Tori Nguyen
Alan Rembach
Rebecca L. Rumble
Stephanie Rainey-Smith, Edith Cowan UniversityFollow
Ralph Martins, Edith Cowan UniversityFollow
Michael F. Fenech
The Australian Imaging, Biomarkers and Lifestyle Study Research Group
Abstract
Previous studies have suggested that mild cognitive impairment (MCI) may be reflective of the early stages of neurodegenerative disorders such as Alzheimer’s disease (AD). The hypothesis was that cytokeratin (CK) 14 expression can be used as a biomarker in isolated buccal mucosa to identify individuals with MCI or AD from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging. Visual assessment of buccal cell CK14 expression was carried out using immunofluorescence techniques. The frequency of basal buccal cells expressing CK14 was significantly lower in the MCI (P=0.0002) and AD (P
RAS ID
21503
Document Type
Journal Article
Date of Publication
2015
Faculty
Faculty of Health, Engineering and Science
School
School of Medical Sciences / Centre of Excellence for Alzheimer's Disease Research and Care
Copyright
subscription content
Publisher
Bentham Science Publishers B.V.
Recommended Citation
Leifert, W. R., Tuli, J. F., François, M., Nguyen, T., Rembach, A., Rumble, R. L., Rainey-Smith, S., Martins, R., Fenech, M. F., & Research Group, T. (2015). Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment And Alzheimer’s Disease In The AIBL Study Of Aging. DOI: https://doi.org/10.2174/1567205012666150302154650
Comments
R Leifert, W., Ferdoush Tuli, J., Francois, M., Nguyen, T., Rembach, A., L Rumble, R., ... & F Fenech, M. (2015). Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment and Alzheimer’s Disease in the AIBL Study of Aging. Current Alzheimer Research, 12(3), 233-241. Available here